Immix Biopharma, Inc. (IMMX)

Last Closing Price: 2.04 (2023-06-02)

Company Description

Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-8.23M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 2.42
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -62.89%
Return on Assets (Trailing 12 Months) -58.18%
Current Ratio (Most Recent Fiscal Quarter) 8.85
Quick Ratio (Most Recent Fiscal Quarter) 8.85
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $0.94
Earnings per Share (Most Recent Fiscal Quarter) --
Earnings per Share (Most Recent Fiscal Year) --
Diluted Earnings per Share (Trailing 12 Months) --
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 15.03M
Free Float 6.63M
Market Capitalization $30.67M
Average Volume (Last 20 Days) 0.51M
Beta (Past 60 Months) -0.07
Percentage Held By Insiders (Latest Annual Proxy Report) 55.90%
Percentage Held By Institutions (Latest 13F Reports) 2.15%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%